Bruker Co. (NASDAQ:BRKR) Shares Sold by First Trust Advisors LP

First Trust Advisors LP cut its holdings in Bruker Co. (NASDAQ:BRKR) by 71.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 189,513 shares of the medical research company’s stock after selling 474,127 shares during the period. First Trust Advisors LP owned 0.12% of Bruker worth $7,709,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Advisor Group Holdings Inc. acquired a new position in Bruker during the first quarter worth $616,000. State Street Corp lifted its stake in Bruker by 7.4% during the first quarter. State Street Corp now owns 1,566,923 shares of the medical research company’s stock worth $56,190,000 after purchasing an additional 108,577 shares in the last quarter. AQR Capital Management LLC lifted its stake in Bruker by 54.8% during the first quarter. AQR Capital Management LLC now owns 280,953 shares of the medical research company’s stock worth $10,075,000 after purchasing an additional 99,441 shares in the last quarter. Jane Street Group LLC acquired a new position in Bruker during the first quarter worth $233,000. Finally, Norges Bank acquired a new position in Bruker during the fourth quarter worth $77,325,000. Institutional investors own 69.96% of the company’s stock.

NASDAQ:BRKR opened at $44.62 on Friday. The firm has a market capitalization of $6.88 billion, a PE ratio of 39.49, a price-to-earnings-growth ratio of 4.32 and a beta of 1.38. The business’s fifty day moving average price is $41.23 and its 200 day moving average price is $42.46. The company has a debt-to-equity ratio of 1.04, a current ratio of 2.60 and a quick ratio of 1.78. Bruker Co. has a 12 month low of $30.78 and a 12 month high of $54.49.

Bruker (NASDAQ:BRKR) last posted its earnings results on Wednesday, May 6th. The medical research company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.22 by ($0.08). The business had revenue of $424.00 million during the quarter, compared to analysts’ expectations of $438.04 million. Bruker had a net margin of 8.69% and a return on equity of 25.09%. The business’s quarterly revenue was down 8.1% compared to the same quarter last year. During the same period last year, the company earned $0.28 EPS. As a group, equities analysts anticipate that Bruker Co. will post 1.15 EPS for the current year.

In related news, Director Cynthia M. Friend sold 1,800 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $40.57, for a total value of $73,026.00. Following the transaction, the director now owns 11,857 shares of the company’s stock, valued at $481,038.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 26.80% of the company’s stock.

A number of research firms have commented on BRKR. Bank of America upped their price target on Bruker from $43.00 to $49.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Cleveland Research lowered Bruker from a “buy” rating to a “neutral” rating and set a $37.50 price objective on the stock. in a research report on Friday, May 1st. Wells Fargo & Co cut their price objective on Bruker from $50.00 to $42.00 and set an “overweight” rating on the stock in a research report on Thursday, May 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Bruker in a research report on Wednesday, May 13th. Finally, UBS Group cut their price objective on Bruker from $53.00 to $41.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. Bruker presently has an average rating of “Hold” and an average price target of $42.95.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Read More: Fundamental Analysis – How It Helps Investors

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.